Empiric treatment of infections in granulocytopenic patients with acute leukemia: A study of amikacin-carbenicillin-cotrimoxazole

A. Cortelezzi, F. Radaelli, R. Penagini, E. M. Pogliani

Research output: Contribution to journalArticle

Abstract

The amikacin-carbenicillincotrimoxazole combination was used as an empiric treatment for febrile episodes in patients with acute leukemia and severe granulocytopenia. The choice of drugs was based on finding in our institute that the majority of infections are caused by gram-negative rods, particularly Pseudomonas, with high percentage of strains resistant to gentamycin and tobramycin. Granulocyte transfusions were given to the patients who did not show satisfactory clinical improvement 48 h after start of antibiotic therapy. There were cures in 84.6% of the febrile episodes treated with this antibiotic combination, including five of eight episodes of microbiologically confirmed bacteremia. Survival after 21 days of antibiotic therapy amounted to 89.1%. Renal toxicity occurred in 10.9% of the episodes treated. The prompt use of this antibiotic combination seems to be a safe and efficacious therapeutic tool for treating these high-risk patients.

Original languageEnglish
Pages (from-to)520-523
Number of pages4
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Volume20
Issue number11
Publication statusPublished - 1982

Fingerprint

Carbenicillin
Amikacin
Sulfamethoxazole Drug Combination Trimethoprim
Leukemia
Anti-Bacterial Agents
Infection
Fever
Agranulocytosis
Tobramycin
Therapeutics
Bacteremia
Pseudomonas
Gentamicins
Granulocytes
Toxicity
Kidney
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology

Cite this

@article{245aa9ff8e72446c9131929e02e34649,
title = "Empiric treatment of infections in granulocytopenic patients with acute leukemia: A study of amikacin-carbenicillin-cotrimoxazole",
abstract = "The amikacin-carbenicillincotrimoxazole combination was used as an empiric treatment for febrile episodes in patients with acute leukemia and severe granulocytopenia. The choice of drugs was based on finding in our institute that the majority of infections are caused by gram-negative rods, particularly Pseudomonas, with high percentage of strains resistant to gentamycin and tobramycin. Granulocyte transfusions were given to the patients who did not show satisfactory clinical improvement 48 h after start of antibiotic therapy. There were cures in 84.6{\%} of the febrile episodes treated with this antibiotic combination, including five of eight episodes of microbiologically confirmed bacteremia. Survival after 21 days of antibiotic therapy amounted to 89.1{\%}. Renal toxicity occurred in 10.9{\%} of the episodes treated. The prompt use of this antibiotic combination seems to be a safe and efficacious therapeutic tool for treating these high-risk patients.",
author = "A. Cortelezzi and F. Radaelli and R. Penagini and Pogliani, {E. M.}",
year = "1982",
language = "English",
volume = "20",
pages = "520--523",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0174-4879",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "11",

}

TY - JOUR

T1 - Empiric treatment of infections in granulocytopenic patients with acute leukemia

T2 - A study of amikacin-carbenicillin-cotrimoxazole

AU - Cortelezzi, A.

AU - Radaelli, F.

AU - Penagini, R.

AU - Pogliani, E. M.

PY - 1982

Y1 - 1982

N2 - The amikacin-carbenicillincotrimoxazole combination was used as an empiric treatment for febrile episodes in patients with acute leukemia and severe granulocytopenia. The choice of drugs was based on finding in our institute that the majority of infections are caused by gram-negative rods, particularly Pseudomonas, with high percentage of strains resistant to gentamycin and tobramycin. Granulocyte transfusions were given to the patients who did not show satisfactory clinical improvement 48 h after start of antibiotic therapy. There were cures in 84.6% of the febrile episodes treated with this antibiotic combination, including five of eight episodes of microbiologically confirmed bacteremia. Survival after 21 days of antibiotic therapy amounted to 89.1%. Renal toxicity occurred in 10.9% of the episodes treated. The prompt use of this antibiotic combination seems to be a safe and efficacious therapeutic tool for treating these high-risk patients.

AB - The amikacin-carbenicillincotrimoxazole combination was used as an empiric treatment for febrile episodes in patients with acute leukemia and severe granulocytopenia. The choice of drugs was based on finding in our institute that the majority of infections are caused by gram-negative rods, particularly Pseudomonas, with high percentage of strains resistant to gentamycin and tobramycin. Granulocyte transfusions were given to the patients who did not show satisfactory clinical improvement 48 h after start of antibiotic therapy. There were cures in 84.6% of the febrile episodes treated with this antibiotic combination, including five of eight episodes of microbiologically confirmed bacteremia. Survival after 21 days of antibiotic therapy amounted to 89.1%. Renal toxicity occurred in 10.9% of the episodes treated. The prompt use of this antibiotic combination seems to be a safe and efficacious therapeutic tool for treating these high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=0019920078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019920078&partnerID=8YFLogxK

M3 - Article

C2 - 6983502

AN - SCOPUS:0019920078

VL - 20

SP - 520

EP - 523

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0174-4879

IS - 11

ER -